Back to Search
Start Over
GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts
- Source :
- Neuropharmacology. 56:174-181
- Publication Year :
- 2009
- Publisher :
- Elsevier BV, 2009.
-
Abstract
- Valerian extracts have been used for centuries to alleviate restlessness and anxiety albeit with unknown mechanism of action in vivo. We now describe a specific binding site on GABA(A) receptors with nM affinity for valerenic acid and valerenol, common constituents of valerian. Both agents enhanced the response to GABA at multiple types of recombinant GABA(A) receptors. A point mutation in the beta2 or beta3 subunit (N265M) of recombinant receptors strongly reduced the drug response. In vivo, valerenic acid and valerenol exerted anxiolytic activity with high potencies in the elevated plus maze and the light/dark choice test in wild type mice. In beta3 (N265M) point-mutated mice the anxiolytic activity of valerenic acid was absent. Thus, neurons expressing beta3 containing GABA(A) receptors are a major cellular substrate for the anxiolytic action of valerian extracts.
- Subjects :
- Valerian
Elevated plus maze
Patch-Clamp Techniques
medicine.drug_class
Pharmacology
Biology
Tritium
Choice Behavior
Anxiolytic
Membrane Potentials
Mice
Cellular and Molecular Neuroscience
chemistry.chemical_compound
In vivo
medicine
Animals
Humans
Maze Learning
Receptor
gamma-Aminobutyric Acid
Cell Line, Transformed
Analysis of Variance
Dose-Response Relationship, Drug
Plant Extracts
GABAA receptor
Brain
Receptors, GABA-A
biology.organism_classification
Valerenic acid
Mice, Mutant Strains
Rats
Protein Subunits
Anti-Anxiety Agents
Indenes
Mechanism of action
Biochemistry
chemistry
Mutation
Mutagenesis, Site-Directed
medicine.symptom
Sesquiterpenes
Allosteric Site
Protein Binding
Subjects
Details
- ISSN :
- 00283908
- Volume :
- 56
- Database :
- OpenAIRE
- Journal :
- Neuropharmacology
- Accession number :
- edsair.doi.dedup.....7dbcb9056c1446af5f6792c10e075581
- Full Text :
- https://doi.org/10.1016/j.neuropharm.2008.06.013